MorningStar Launches SmartVascular Dx Test in Western US, Expands Payer Coverage
MorningStar Laboratories, LLC (MSL), a developer of precision diagnostic tests, has announced the availability of its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, in the Western United States. This diagnostic tool focuses on enhancing vascular health monitoring and early detection of vascular diseases, which are critical for timely and targeted healthcare interventions. The availability of this test in the Western U.S. represents a strategic regional expansion to address unmet clinical needs in vascular diagnostics.
MSL has expanded its insurance network participation, now being in-network with Blue Cross Blue Shield of Arizona. Furthermore, the company has established contracts for claim reimbursements with major payers such as United Healthcare, Aetna, Cigna, and Humana on a nationwide basis, albeit on an out-of-network basis for PPO and Medicare Advantage plan members. Importantly, the SmartVascular Dx test is covered by Medicare, enhancing its accessibility for eligible patients.
In terms of operational infrastructure, MSL has partnered with My One Medical Source® (MOMS), a SaaS platform that connects laboratories with Medical Access Points/Providers™ (MAPs) to facilitate specimen collection nationwide. This collaboration enhances the logistics of specimen collection, supporting scalable deployment and integration of the SmartVascular Dx test into various healthcare settings.
MorningStar Laboratories operates as a CLIA-certified and CAP-accredited specialty diagnostic laboratory, combining multiple sources of clinical data using proprietary analytics to develop tests that detect high-risk diseases related to endothelial and vascular inflammatory conditions. Their compliance with Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), and ISO 15189 standards positions them as a reliable clinical diagnostics provider in the U.S.
The launch of SmartVascular Dx in the Western region, combined with strategic payer partnerships and logistics support from MOMS, places MorningStar Laboratories to potentially influence vascular care practice patterns by offering advanced diagnostic capabilities. This development may prompt insurers and providers to reassess diagnostic strategies for vascular diseases, impacting payer/provider workflows and reimbursement frameworks.
Healthcare professionals and clinics interested in integrating the SmartVascular Dx test into their practice are encouraged to contact MorningStar Laboratories directly. Continued expansion of such precision diagnostics is reflective of ongoing trends in personalized medicine, highlighting the intersection of technology, analytics, and insurance dynamics within the healthcare sector.